ResMed does not currently offer a direct stock purchase plan. If you wish to purchase ResMed common stock, please contact a stockbroker.

ResMed currently pays a quarterly dividend. Dividend information is available in the Dividend History section of the website. ResMed does not offer a dividend reinvestment program.

ResMed’s Annual Reports are available in Adobe Acrobat format in the Annual Reports section of our website. To get a copy mailed to you, email us at , call 800-424-0737 #6, or write to Investor Relations, ResMed Inc., 9001 Spectrum Center Blvd San Diego, CA 92123.

By e-mail at
By phone for IR General Inquiries call: 800-424-0737 #6.
By fax: 858-746-2830.
By mail: Investor Relations, ResMed Inc., 9001 Spectrum Center Blvd, San Diego, CA 92123

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD" and on the Australian Securities Exchange (ASX) under the symbol “RMD.AX”.

Registered shareholders have shares registered in their own name. While not required, registered shareholders may have a stock certificate denoting the number of shares owned. Shareholders who deposit their shares in an electronic brokerage account hold the shares in "street name" because their shares are legally registered in the broker's (street) name, although the shareholder retains beneficial ownership of the shares.

ResMed's fiscal year ends on June 30th.

Inquiries concerning the transfer or exchange of RMD shares, lost stock certificates, duplicate mailings or change of address should be directed to our Transfer Agent and Registrar:

Computershare, Inc.
PO Box 30170
College Station, TX 77842
Telephone: +1 800-962-4284
TDD/TTY: +1 800-952-9245 (within USA) or +1 781-575-4592 (outside USA)

Computershare, Inc.
Level 3
60 Carrington Street
Sydney NSW 2000
Tel: +61 2 8234 5000 Website:

A listing of the members of ResMed’s Board of Directors can be found under the Corporate Governance section.

If you are a member of the media, please contact Rowena Kelley at or 858-289-7272. For additional information you may also visit our Newsroom.